| Title |
Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors
|
|---|---|
| Published in |
Journal of Neuro-Oncology, August 2018
|
| DOI | 10.1007/s11060-018-2957-7 |
| Pubmed ID | |
| Authors |
Takahiro Sasaki, Junya Fukai, Yoshinori Kodama, Takanori Hirose, Yoshiko Okita, Shusuke Moriuchi, Masahiro Nonaka, Naohiro Tsuyuguchi, Yuzo Terakawa, Takehiro Uda, Yusuke Tomogane, Manabu Kinoshita, Namiko Nishida, Shuichi Izumoto, Yoshikazu Nakajima, Hideyuki Arita, Kenichi Ishibashi, Tomoko Shofuda, Daisuke Kanematsu, Ema Yoshioka, Masayuki Mano, Koji Fujita, Yuji Uematsu, Naoyuki Nakao, Kanji Mori, Yonehiro Kanemura |
| Abstract |
This study investigates the current state of clinical practice and molecular analysis for elderly patients with diffuse gliomas and aims to elucidate treatment outcomes and prognostic factors of patients with glioblastomas. We collected elderly cases (≥ 70 years) diagnosed with primary diffuse gliomas and enrolled in Kansai Molecular Diagnosis Network for CNS Tumors. Clinical and pathological characteristics were analyzed retrospectively. Various factors were evaluated in univariate and multivariate models to examine their effects on overall survival. Included in the study were 140 elderly patients (WHO grade II: 7, III: 19, IV: 114), median age was 75 years. Sixty-seven patients (47.9%) had preoperative Karnofsky Performance Status score of ≥ 80. All patients underwent resection (gross-total: 20.0%, subtotal: 14.3%, partial: 39.3%, biopsy: 26.4%). Ninety-six of the patients (68.6%) received adjuvant treatment consisting of radiotherapy (RT) with temozolomide (TMZ). Seventy-eight of the patients (75.0%) received radiation dose of ≥ 50 Gy. MGMT promoter was methylated in 68 tumors (48.6%), IDH1/2 was wild-type in 129 tumors (92.1%), and TERT promoter was mutated in 78 of 128 tumors (60.9%). Median progression-free and overall survival of grade IV cases was 8.2 and 13.6 months, respectively. Higher age (≥ 80 years) and TERT promoter mutated were associated with shorter survival. Resection and adjuvant RT + TMZ were identified as independent factors for good prognosis. This community-based study reveals characteristics and outcomes of elderly glioma patients in a real-world setting. Elderly patients have several potential factors for poor prognosis, but resection followed by RT + TMZ could lengthen duration of survival. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 50% |
| United Kingdom | 1 | 13% |
| Unknown | 3 | 38% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 38% |
| Science communicators (journalists, bloggers, editors) | 3 | 38% |
| Scientists | 2 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 32 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 5 | 16% |
| Student > Master | 4 | 13% |
| Researcher | 3 | 9% |
| Student > Ph. D. Student | 3 | 9% |
| Student > Doctoral Student | 1 | 3% |
| Other | 4 | 13% |
| Unknown | 12 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 41% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 9% |
| Neuroscience | 2 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Unknown | 12 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 December 2018.
All research outputs
#6,895,954
of 23,098,660 outputs
Outputs from Journal of Neuro-Oncology
#884
of 2,994 outputs
Outputs of similar age
#117,722
of 331,034 outputs
Outputs of similar age from Journal of Neuro-Oncology
#21
of 68 outputs
Altmetric has tracked 23,098,660 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 2,994 research outputs from this source. They receive a mean Attention Score of 4.2. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,034 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 68 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.